Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1990 Feb 3;300(6720):275–276. doi: 10.1136/bmj.300.6720.275

Interleukin 2.

T J Hamblin 1
PMCID: PMC1661905  PMID: 2106954

Full text

PDF
275

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., Mier J. W., Parkinson D. R., Gould J. A., Berkman E. M., Kaplan M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988 Jun 16;318(24):1557–1563. doi: 10.1056/NEJM198806163182401. [DOI] [PubMed] [Google Scholar]
  2. Bloom M. Cancer M.D.'s clash over interleukin therapy. Science. 1987 Jan 9;235(4785):154–155. doi: 10.1126/science.3492042. [DOI] [PubMed] [Google Scholar]
  3. Christiansen N. P., Skubitz K. M., Nath K., Ochoa A., Kennedy B. J. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. Am J Med. 1988 Jun;84(6):1072–1075. doi: 10.1016/0002-9343(88)90314-2. [DOI] [PubMed] [Google Scholar]
  4. Cotran R. S., Gimbrone M. A., Jr, Bevilacqua M. P., Mendrick D. L., Pober J. S. Induction and detection of a human endothelial activation antigen in vivo. J Exp Med. 1986 Aug 1;164(2):661–666. doi: 10.1084/jem.164.2.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Denicoff K. D., Rubinow D. R., Papa M. Z., Simpson C., Seipp C. A., Lotze M. T., Chang A. E., Rosenstein D., Rosenberg S. A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987 Sep;107(3):293–300. doi: 10.7326/0003-4819-107-2-293. [DOI] [PubMed] [Google Scholar]
  6. Kotasek D., Vercellotti G. M., Ochoa A. C., Bach F. H., White J. G., Jacob H. S. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res. 1988 Oct 1;48(19):5528–5532. [PubMed] [Google Scholar]
  7. Mitchell M. S., Kempf R. A., Harel W., Shau H., Boswell W. D., Lind S., Bradley E. C. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. J Clin Oncol. 1988 Mar;6(3):409–424. doi: 10.1200/JCO.1988.6.3.409. [DOI] [PubMed] [Google Scholar]
  8. Moertel C. G. On lymphokines, cytokines, and breakthroughs. JAMA. 1986 Dec 12;256(22):3141–3141. [PubMed] [Google Scholar]
  9. Nora R., Abrams J. S., Tait N. S., Hiponia D. J., Silverman H. J. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989 Jan 4;81(1):59–63. doi: 10.1093/jnci/81.1.59. [DOI] [PubMed] [Google Scholar]
  10. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  11. Schwartzentruber D., Lotze M. T., Rosenberg S. A. Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer. 1988 Dec 1;62(11):2350–2353. doi: 10.1002/1097-0142(19881201)62:11<2350::aid-cncr2820621116>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  12. Sosman J. A., Kohler P. C., Hank J. A., Moore K. H., Bechhofer R., Storer B., Sondel P. M. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst. 1988 Nov 16;80(18):1451–1461. doi: 10.1093/jnci/80.18.1451. [DOI] [PubMed] [Google Scholar]
  13. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES